blog counter

Caliper Life Sciences Inc.
Medical Devices & Tech
68 Elm St.
Hopkinton, MA 1748 USA
phone: 508-435-9500
fax: 508-435-3439
Symbol CALP
Exchange NASDAQ
Founded 0
Employees 443
www.calipertech.com
Research Sector Medical Devices & Tech
Summary Description
Analytical tools based on labchip technology for automation of laboratory procedures.
Management
E. Kevin Hrusovsky, President and Chief Executive Officer; Thomas T. Higgins, Executive Vice President and Chief Financial Officer; David M. Manyak, Ph.D., Executive Vice President, Drug Discovery Services; Bruce J. Bal, Senior Vice President, Operations & Aftermarket Business; Steven E. Creager, Senior Vice President, General Counsel and Secretary; William C. Kruka, Senior Vice President, Business Development; Enrique Bernal, Vice President, Instrument R&D; Paula J. Cassidy, Vice President, Human Resources; Andrea W. Chow, Ph.D., Vice President, Microfluidics R&D; Bradley W. Rice, Ph.D., Vice President, Biophotonic Imaging R&D; Mark T. Roskey, Ph.D., Vice President, Reagents and Applied Biology; Jean-Louis Rufener, Vice President, International Operations; Board of Directors, Daniel L. Kisner, M.D., Chairman of the Board; David Milligan, Ph. D., Vice Chairman of the Board, Former Chief Scientific Officer, Abbott Laboratories; Van Billet, Chief Financial Officer, The Berwind Company LLC; Robert C. Bishop, Ph. D., President and Chief Executive Officer, AutoImmune, Inc.; David Carter Former CEO and Chairman, Xenogen Co.; Allan L. Comstock, Former Vice President and Controller of Atlantic Richfield Company (ARCO); Michael Eisenson, Managing Director and CEO, Charlesbank Capital Partners; Kevin Hrusovsky, President and Chief Executive Officer; Kathryn Tunstall, Former President and Chief Executive Officer, Conceptus
Ownership
Financials Mkt Cap :123


* numbers in thousands

Recent Results
For the quarter ended September 2006, total revenues for were $26.5 million, an increase of 24% from $21.3 million in the same period in 2005.
 
Keywords
Lab-on-a-chip, microfabrication, microfluidics, automatic workstation, nanotechnology, j2008

Comment | Printable Version | Jul. 01, 2008
If you work for Caliper Life Sciences Inc. and want to update this profile, click here

Description
Caliper Life Science develops automated analytical tools for DNA, RNA, protein and cell-based analysis in life science. Caliper's product is based on Labchip technologies, which miniaturize, integrate and automate many laboratory processes, and enable researchers in pharmaceutical and biotech companies to perform experiments faster and more cost effectively. Caliper aims to expand its product lines in the areas of drug discovery and development, genomics and proteomics and molecular diagnostics.
Products / Services
Two types of products are provided by Caliper: install base and consumables. Install base refers to various integratable instruments and workstations, for applications such as automated DNA analysis, enzymatic and cell-based assays, as well as liquid handling, plate storage and management. Consumables refer to the disposable items used in experiments such as various chips designed for different biological experiments, pipet tips, filters and DNA hybridization cassettes. Caliper also provides labchips and workstation parts for commercial partners to develop their own instruments. These products and services are provided under standard or customized OEM agreements.
Technology / Differentiation
Caliper's lab-on-a-chip devices can perform routine laboratory analysis procedures in a speedy and precise way using two technology platforms: microfabrication and microfluidics. Microfabrication is the use of manufacturing methods similar to those used in the semiconductor industry to create intricate designs of interconnected channels that are extremely small and precise. Microfluidics is the technology to move the chemical reagents and test samples in these microchannels.
Market / Customers
Caliper's products have the potential to reach three large markets: Discovery and Drug development ($2.7 B), Genomics and Proteomics ($8.3B) and Molecular diagnostics ($1.2 B). The size of its current accessible market is $580M in discovery and development and $500M in genomics and proteomics. Caliper sells its products through two distribution channels: one directly to the pharmaceutical and biotech companies such as Johnson and Johnson, Pfizer, GSK; the other to commercial partners to sell to end-users, these partners include Agilent, BioRad, Affymetrix and Qiagen. Agilent has been the largest commercial partner of Caliper since 1999: Agilent accounted for 39% of total revenue in 2002.
Funding
Caliper completed its 76M initial public offering in Dec. 1999. A private placement of $105 million In August 2000. Caliper had 60M cash by the end of 2003, with 28M shares outstanding.